Stockreport

Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for ...

Corvus Pharmaceuticals, Inc.  (CRVS) 
Last corvus pharmaceuticals, inc. earnings: 4/30 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: corvuspharma.com
PDF Trial is evaluating ciforadenant as a potential first line therapy for metastatic renal cell cancer (RCC) in combination with ipilimumab (anti-CTLA-4) and nivolumab (ant [Read more]